US20140039064A1 - Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing - Google Patents

Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing Download PDF

Info

Publication number
US20140039064A1
US20140039064A1 US14/009,218 US201214009218A US2014039064A1 US 20140039064 A1 US20140039064 A1 US 20140039064A1 US 201214009218 A US201214009218 A US 201214009218A US 2014039064 A1 US2014039064 A1 US 2014039064A1
Authority
US
United States
Prior art keywords
skin
signs
compound
gingerone
ageing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/009,218
Other languages
English (en)
Inventor
Maria Dalko
Sophie SAUSSAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Priority to US14/009,218 priority Critical patent/US20140039064A1/en
Assigned to L'OREAL reassignment L'OREAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DALKO, MARIA, SAUSSAY, SOPHIE
Publication of US20140039064A1 publication Critical patent/US20140039064A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35Ketones, e.g. benzophenone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients

Definitions

  • the present invention relates to the field of ageing and of the signs that are associated therewith, on the skin. It relates in particular to the adjustment of the equilibrium between the proliferation and the differentiation of the epidermal cells.
  • the skin constitutes a physical barrier between the body and its surroundings. It is constituted of two tissues: the epidermis and the dermis.
  • the dermis provides the epidermis with a solid support. It is also its nourishing element. It is formed mainly from fibroblasts and an extracellular matrix, which is itself composed mainly of collagen, elastin and a substance known as ground substance, these components being synthesized by the fibroblast. Leukocytes, mast cells or else tissue macrophages are also found therein. It also contains blood vessels and nerve fibres.
  • the epidermis is a desquamating pluristratified epithelium that is 100 ⁇ m thick on average and is conventionally divided into a basal layer of keratinocytes that constitutes the germinal layer of the epidermis, a spinous layer constituted of several layers of polyhedral cells positioned on the germinal cells, a granular layer constituted of flattened cells containing distinct cytoplasmic inclusions, keratohyalin granules, and finally an upper layer known as the cornified layer (or stratum corneum), constituted of keratinocytes at the terminal stage of their differentiation, known as corneocytes. These are mummified anucleated cells which derive from keratinocytes.
  • the stack of these corneocytes constitutes the cornified layer that is responsible, inter alia, for the barrier function of the epidermis, i.e. it constitutes a barrier against external attacks, especially chemical, mechanical or infectious attacks and it also makes it possible to protect the body from water loss.
  • Epidermal differentiation follows a process of continuous and oriented maturation in which the basal keratinocytes transform while migrating so as to result in the formation of corneocytes, dead cells that are completely keratinized.
  • This differentiation is the result of perfectly coordinated phenomena which will result in the thickness of the epidermis being kept constant and thus ensure the homeostasis of the epidermis.
  • This goes through a regulation of the number of cells that enter into the differentiation process and of the number of cells that desquamate. In the course of the normal desquamation process, only the most superficial corneocytes detach from the surface of the epidermis.
  • Keratins are insoluble proteins produced by the epithelial cells in the form of structurally well organized filaments. These proteins are the main marker of differentiation since throughout epidermal differentiation, various types of keratin will be more or less expressed by the keratinocytes.
  • Filaggrin or filagrin
  • a protein present in keratohyalin granules is produced during the final stages of the differentiation of the epidermis. It is especially involved in the maturation process of the cornified layer by enabling type I and type II keratins to be arranged into coils. This protein thus enables the formation of the cytoplasmic matrix of the surface corneocytes which in particular gives the skin its normal thickness, its smooth appearance and its light-reflecting properties.
  • filaggrin via its degradation within corneocytes, filaggrin provides water-soluble substances having a high osmotic power (natural moisturizing factors or NMFs) that enable a good hydration of the cornified layer of the skin to be maintained and thus avoid the feelings of “dry skin”. Filaggrin therefore enables the barrier function of the epidermis to be maintained and makes it possible to avoid drying out the skin.
  • gingerone and some of the derivatives thereof increased the expression of filaggrin in the keratinocytes.
  • filaggrin is a marker of the differentiation of keratinocytes
  • gingerone and some of the derivatives thereof therefore have an effect of stimulating the differentiation of these cells and thus the maturation of the cornified layer. They thus enable the skin to retain or regain a normal thickness, to also have a smooth appearance, i.e without, or with fewer, wrinkles and fine lines than before their use and a more radiant, less dull complexion.
  • filaggrin is involved in the skin hydration process, by increasing the expression of this protein in keratinocytes, these compounds enable the skin to fully carry out its barrier function while avoiding, in particular, the drying out thereof. They therefore make it possible to reestablish or maintain good hydration of the skin.
  • Gingerone (INCI name: Zingerone), is a phenolic compound from the vanilloid family. Its formula and those of several of its derivatives are given below. Ginger ( Zingiber officinale ), mango, cranberry or raspberry may be natural sources of gingerone. Ginger, and in particular ginger oleoresin, is however the main source thereof. This molecule is to a large extent responsible for the hot flavour of ginger.
  • Gingerone has already been cited among the ingredients of topical anti-ageing care compositions but it was used as a blood circulation “accelerator” (JP 2004323401, JP 2005066831) or as a hyperemizing agent (EP 1 938 789) or as an antioxidant (EP 1 932 514) or as a caustic, bitter or acid substance (JP 2004210656).
  • gingerone and some of the derivatives thereof have never been described as being pro-differentiating for keratinocytes and as being able to be used specifically for treating or delaying the appearance of the signs of skin ageing.
  • these compounds are of general formula (I) in which:
  • the compound of general formula (I) mentioned above will preferably be chosen, alone or as a mixture, from the following compounds:
  • the preferred compound will be chosen from gingerone (or zingerone) or ethyl gingerone.
  • the gingerone may be, for example, supplied by the company Aldrich. Most preferred is ethyl gingerone.
  • Compounds 2 and 7 may be, for example, supplied by the company SinoChemExper.
  • the compounds of general formula (I), as targeted above, could be used in the form of a more or less purified molecule of natural or synthetic origin. They will preferably be of natural origin. In particular, some of these compounds could be provided in the form of plant extracts containing them, and especially in the form of an extract of ginger, of mango, of cranberry and/or of raspberry.
  • Such compounds may be synthesized via synthesis pathways known in the prior art. They may in particular be prepared from commercial vanillin or ethyl vanillin. Gingerone, for example, could be obtained via the condensation of vanillin by acetone, followed by a hydrogenation.
  • the expression “cutaneous signs of ageing” is understood to mean any modification in the external appearance of the skin due to ageing, whether chronobiological and/or photoinduced, such as, for example, wrinkles and fine lines, withered skin, flaccid skin, slack skin, thinned skin, dry skin, dull skin that lacks radiance, heterogeneity of the complexion and of the surface of the skin.
  • the signs of chronobiological or chronological ageing correspond to internal degradations of the skin due to the intrinsic ageing of the individuals.
  • the signs of photoinduced ageing (or photoageing) correspond to internal degradations of the skin following exposure to ultraviolet radiation.
  • skin is understood to mean, for the purposes of the invention, the whole of the body covering, and in particular the skin, mucous membranes and scalp.
  • the reduction of the signs of skin ageing and/or the delaying of their appearance, via the use of the compounds according to the present invention, takes place in particular owing to the increase or improvement in the differentiation of the epidermal cells and/or the increase or stimulation in particular of the expression of filaggrin in the epidermal keratinocytes.
  • compositions used according to the invention are cosmetic compositions, i.e. they are intended to improve the aesthetic appearance of the individual.
  • the use according to the present invention is especially effective for combating the signs, in particular aesthetic signs, of chronobiological and/or photoinduced ageing of the epidermis.
  • combating the signs of chronobiological ageing of the skin will preferably be targeted.
  • the present invention is thus effective in any person regardless of their age.
  • the individuals preferably targeted will be individuals of more than 30 years old, preferably more than 40 years old.
  • the signs of skin ageing are preferably chosen from the appearance of wrinkles and fine lines and/or the weakening and/or the slackening and/or the withering and/or the thinning and/or the dryness and/or the dull and/or non-radiant appearance and/or the complexion and/or the heterogeneous surface of the skin.
  • the compound of general formula (I) as targeted above is present, in a composition comprising a physiologically acceptable medium, in a content between 0.1% and 10% by weight relative to the total weight of said composition.
  • a “physiologically acceptable medium” is, according to the invention, a cosmetically acceptable medium that is compatible with the skin, the mucous membranes, the nails and/or the hair.
  • cosmetically acceptable medium is understood to mean a medium that has no unpleasant appearance, and that does not cause the user any unacceptable stinging, tautness or redness.
  • physiologically acceptable medium will be adapted to the nature of the support onto which the composition is to be applied, and also to the form in which the composition is intended to be packaged, in particular solid or fluid at room temperature and atmospheric pressure.
  • composition is preferably suitable for topical application.
  • the composition according to the invention of course comprises a cosmetically acceptable support, i.e. a support that is compatible with the skin, the mucous membranes, the nails, the hair, and may be in any galenic form normally used for a topical application, in particular in the form of an aqueous, aqueous-alcoholic or oily solution, an oil-in-water or water-in-oil or multiple emulsion, an aqueous or oily gel, a liquid, pasty or solid anhydrous product, a suspension or a dispersion; for example a dispersion of oil in an aqueous phase using spherules, it being possible for these spherules to be polymeric nanoparticles, such as nanospheres and nanocapsules, or better still lipid vesicles of ionic and/or nonionic type.
  • a cosmetically acceptable support i.e. a support that is compatible with the skin, the mucous membranes, the nails, the hair, and
  • This composition may be more or less fluid and may have the appearance of a white or coloured cream, an ointment, a milk, a lotion, a serum, a paste or a foam. It can optionally be applied to the skin in aerosol form. It can also be in solid form, for example in the form of a stick. It can be used as a care product or as a cleansing product or as a makeup product.
  • the composition of the invention may contain adjuvants that are common in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, screening agents, pigments, chelating agents, odour absorbers and colorants.
  • adjuvants that are common in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, screening agents, pigments, chelating agents, odour absorbers and colorants.
  • the amounts of these various adjuvants are those conventionally used in the fields under consideration, for example from 0.01% to 20% of the total weight of the composition.
  • these adjuvants may be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and/or into the nanoparticles.
  • the proportion of the fatty phase may range from 5% to 80% by weight and preferably from 5% to 50% of the total weight of the composition.
  • the oils, emulsifiers and coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in the field under consideration.
  • the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight and preferably from 0.5% to 20% of the total weight of the composition.
  • oils that can be used in the invention mention may be made of mineral oils, oils of plant origin (apricot oil, sunflower oil), oils of animal origin, synthetic oils, silicone-based oils and fluorinated oils (perfluoropolyethers).
  • oils of plant origin apricot oil, sunflower oil
  • synthetic oils silicone-based oils and fluorinated oils (perfluoropolyethers).
  • fatty substances use may also be made of fatty alcohols (cetyl alcohol), fatty acids and waxes (beeswax).
  • emulsifiers and coemulsifiers that can be used in the invention, mention may for example be made of polyethylene glycol fatty acid esters such as PEG-40 stearate and PEG-100 stearate, and polyol fatty acid esters such as glyceryl stearate and sorbitan tristearate.
  • hydrophilic gelling agents mention may particularly be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
  • compositions according to the invention will contain at least one other active agent chosen from anti-UV screening agents, moisturizers, depigmenting agents, anti-glycation agents, NO-synthase inhibitors, agents for stimulating the synthesis of dermal or epidermal macromolecules and/or for preventing their degradation, agents for stimulating fibroblast or keratinocyte proliferation, myorelaxants or dermo-decontracting agents, tensioning agents, agents for combating pollution or free-radical scavengers, calmatives and active agents that act on the energy metabolism of cells.
  • active agent chosen from anti-UV screening agents, moisturizers, depigmenting agents, anti-glycation agents, NO-synthase inhibitors, agents for stimulating the synthesis of dermal or epidermal macromolecules and/or for preventing their degradation, agents for stimulating fibroblast or keratinocyte proliferation, myorelaxants or dermo-decontracting agents, tensioning agents, agents for combating pollution or free-radical
  • the amount of these additional active agents could vary to a large extent and will be for example from 10 -6 % to 20% by weight, especially from 0.001% to 10% by weight relative to the total weight of the composition.
  • the agents for stimulating fibroblast proliferation may be chosen, for example, from plant proteins or polypeptides, extracted especially from soybean (for example a soybean extract sold by the company LSN under the name Eleseryl SH-VEG 8® or sold by the company Silab under the trade name Raffermine®); and plant hormones such as gibberellins and cytokinins.
  • soybean for example a soybean extract sold by the company LSN under the name Eleseryl SH-VEG 8® or sold by the company Silab under the trade name Raffermine®
  • plant hormones such as gibberellins and cytokinins.
  • the agents for stimulating keratinocyte proliferation that can be used in the composition according to the invention especially comprise retinoids such as retinol and esters thereof, including retinyl palmitate; adenosine, cinnamic acid and derivatives thereof, lycopene and derivatives thereof; phloroglucinol; the walnut meal extracts sold by the company Gattefossé; and the extracts of Solanum tuberosum sold by the company Sederma.
  • retinoids such as retinol and esters thereof, including retinyl palmitate; adenosine, cinnamic acid and derivatives thereof, lycopene and derivatives thereof; phloroglucinol; the walnut meal extracts sold by the company Gattefossé; and the extracts of Solanum tuberosum sold by the company Sederma.
  • the compound of general formula (I) as described above, and/or the composition containing it will be applied to the part of the skin to be treated, in particular to the face, the neck or the hands, daily or several times daily; the application will be repeated every day for a variable period depending on the effects desired, generally from 3 to 6 weeks, but which could be extended or carried out continuously.
  • the compound of general formula (I) as described above or the composition containing it will preferably be applied to the areas of skin affected by the signs of ageing that it is desired to combat.
  • the composition of the invention may be in any suitable form, particularly in the form of a solution to be taken orally, a tablet, a gel capsule, a capsule or alternatively a nutritional food or a nutritional supplement.
  • composition additionally comprises at least one appropriate excipient suitable for oral administration.
  • the oral administration may be daily or several times daily, for example morning and evening. It could be continued for several weeks and/or several months, depending on the effects desired.
  • the method of preparing compound 3 comprises a supplementary reduction step:
  • the compounds according to the invention are prepared here either from commercial vanillin (CAS: 121-33-5), or from commercial ethyl vanillin (CAS: 121-32-4).
  • gingerone compound 1, the chemical formula of which is given above
  • the expression and the location of the marker of filaggrin differentiation are especially studied in keratinocytes in culture which thus makes it possible to evaluate the capacity of this compound to increase the differentiation of these cells.
  • NHEKs Normal human keratinocytes
  • a complete SFM medium is an SFM culture medium supplemented with pituitary extract (25 ⁇ g/ml), EGF (0.25 ng/ml) and gentamicin (25 ⁇ g/ml).
  • the medium was withdrawn and replaced with culture medium that did or did not contain various concentrations of the test product or reference molecules.
  • Calcium chloride and retinoic acid which are known respectively as a stimulator and as an inhibitor of the keratinocyte differentiation, were used as reference molecules for this test.
  • the culture medium was removed and the cells were rinced, fixed, permeabilized then labelled with the primary antibody targeted against the filaggrin protein of interest (in situ immunolabelling). This antibody was then revealed by a secondary antibody coupled to a fluorochrome (GAM-Alexa 488). At the same time, the nuclei of the cells were stained with Hoechst 33258 (bisbenzimide).
  • Image acquisition was carried out using an INCell AnalyzerTM 1000 machine.
  • the labels were quantified by measuring the fluorescence intensity of the proteins relative to the number of nuclei identified by the Hoechst product.
  • Gingerone significantly and dose-dependently increases the expression of the filaggrin protein in normal human epidermal keratinocytes.
  • Gingerone therefore has a pro-differentiating effect on normal human keratinocytes and therefore can thus reduce and/or delay the signs of skin ageing.
  • a lotion is prepared, comprising (% by weight):
  • Example 1 compound tested in Example 1 (gingerone) 0.75% glycerol 2% ethyl alcohol 20% demineralized water qs 100%
  • composition according to the invention applied daily to the face makes it possible to combat the signs of skin ageing.
  • a facial gel comprising (% by weight):
  • composition according to the invention applied daily to the face makes it possible to combat the signs of skin ageing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US14/009,218 2011-04-01 2012-03-30 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing Abandoned US20140039064A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/009,218 US20140039064A1 (en) 2011-04-01 2012-03-30 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1152803 2011-04-01
FR1152803A FR2973230B1 (fr) 2011-04-01 2011-04-01 Utilisation de gingerone ou de ses derives pour diminuer ou retarder les signes du vieillissement de la peau
US201161472659P 2011-04-07 2011-04-07
US14/009,218 US20140039064A1 (en) 2011-04-01 2012-03-30 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing
PCT/EP2012/055886 WO2012131072A1 (en) 2011-04-01 2012-03-30 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/055886 A-371-Of-International WO2012131072A1 (en) 2011-04-01 2012-03-30 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/894,530 Continuation US11602496B2 (en) 2011-04-01 2018-02-12 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing

Publications (1)

Publication Number Publication Date
US20140039064A1 true US20140039064A1 (en) 2014-02-06

Family

ID=44548809

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/009,218 Abandoned US20140039064A1 (en) 2011-04-01 2012-03-30 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing
US15/894,530 Active US11602496B2 (en) 2011-04-01 2018-02-12 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/894,530 Active US11602496B2 (en) 2011-04-01 2018-02-12 Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing

Country Status (8)

Country Link
US (2) US20140039064A1 (es)
EP (2) EP3372220B1 (es)
JP (1) JP6282582B2 (es)
CN (1) CN103957876A (es)
BR (1) BR112013025122B1 (es)
ES (2) ES2673120T3 (es)
FR (1) FR2973230B1 (es)
WO (1) WO2012131072A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014031168B1 (pt) * 2012-06-15 2018-05-02 Symrise Ag Método não terapêutico para a estimulação da biossíntese de hialuronana, composição farmacêutica ou dermatológica, e uso da mesma
FR3029911B1 (fr) 2014-12-12 2018-03-09 L'oreal Nouveaux composes 1,2-diphenylethylene glycol pour lutter contre le vieillissement cutane et utilisation en cosmetique
FR3029910B1 (fr) * 2014-12-12 2019-12-27 L'oreal Nouveaux composes 1-phenyl mono ou polyhydroxypropane, compositions et utilisation en cosmetique
US10568819B2 (en) 2016-10-31 2020-02-25 Sytheon Limited Skin enhancing compositions and methods
FR3059231B1 (fr) * 2016-11-29 2019-09-20 L'oreal Composition comprenant un extrait de truffe et une dihydrochalcone
US11077035B2 (en) 2017-08-11 2021-08-03 Sytheon Limited Hair treatment compositions and methods
US10828241B2 (en) * 2018-06-15 2020-11-10 Sytheon Limited Skin lightening compositions and methods
JP7505680B2 (ja) 2020-07-08 2024-06-25 ハウスウェルネスフーズ株式会社 フィラグリン及び/又はインボルクリン遺伝子発現増強用組成物、並びに、線維芽細胞賦活用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747049A (en) * 1995-07-07 1998-05-05 Shiseido Company, Ltd. Cosmetic composition
JP2003206239A (ja) * 2001-12-28 2003-07-22 Lion Corp 温感組成物及び外用剤組成物
WO2011042358A1 (en) * 2009-10-08 2011-04-14 L'oreal Photoprotective composition based on a 2-alkoxy-4-alkyl ketone phenol compound; use of said compound for increasing the sun protection factor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263909A (ja) * 1985-05-20 1986-11-21 Shiseido Co Ltd 皮膚外用剤
KR920000892B1 (ko) * 1987-10-06 1992-01-30 주식회사 쓰무라 각화증 치료제
JP3536111B2 (ja) * 1992-06-29 2004-06-07 株式会社ナリス化粧品 ムコ多糖類断片化抑制剤および化粧料
JP3597245B2 (ja) * 1995-02-23 2004-12-02 花王株式会社 シワ形成抑制剤
JPH08268859A (ja) * 1995-04-03 1996-10-15 Kao Corp シワ予防・改善化粧料
JPH0930927A (ja) * 1995-07-19 1997-02-04 Kao Corp 皮膚外用剤
NZ299379A (en) * 1995-10-27 1997-04-24 Unilever Plc Topical flavanone-containing composition
JPH09255526A (ja) * 1996-03-27 1997-09-30 Shiseido Co Ltd 老化防止化粧料
AU6256298A (en) * 1998-01-30 1999-08-16 Procter & Gamble Company, The Cosmetic compositions
JP2000136124A (ja) * 1998-10-30 2000-05-16 Pias Arise Kk 皮膚外用剤
JP4391612B2 (ja) * 1999-02-22 2009-12-24 花王株式会社 皮膚化粧料
EP1181007B1 (en) * 1999-06-03 2003-10-15 Unilever Plc Anti-sebum skin care cosmetic compositions containing branched esters
JP2004210656A (ja) 2002-12-27 2004-07-29 Daicho Kikaku:Kk 皮膚用剤
JP2004323401A (ja) 2003-04-23 2004-11-18 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
KR100531980B1 (ko) * 2003-05-02 2005-11-30 최준명 한약재 추출물을 함유하는 화장품 조성물 및 그 제조방법
JP2005013180A (ja) * 2003-06-30 2005-01-20 Taiyo Kagaku Co Ltd 発酵調整組成物
JP2005066831A (ja) 2003-08-22 2005-03-17 Fuji Photo Film Co Ltd インクジェット記録媒体
JP4673851B2 (ja) * 2004-08-30 2011-04-20 花王株式会社 脂肪分解促進剤及び痩身用皮膚外用組成物
CN101083973B (zh) * 2004-12-07 2011-06-29 捷通国际有限公司 使用具有抗氧化性质的芳香物清除氧化的氮和氧物质的方法
US8709502B2 (en) * 2005-09-23 2014-04-29 Chanel Parfums Beaute Extract of Vanilla planifolia
JP4757262B2 (ja) 2005-10-05 2011-08-24 江崎グリコ株式会社 リン酸化糖を含有した皮膚外用剤
JP5061364B2 (ja) * 2006-03-22 2012-10-31 塩野香料株式会社 新規化合物、抗酸化剤及び化粧料、飲食品
US20080025930A1 (en) * 2006-07-31 2008-01-31 Hugo Corstjens Anti-aging Compositions Comprising Menyanthes Trifoliata Leaf Extracts and Methods of Use Thereof
JP2008105949A (ja) * 2006-10-23 2008-05-08 Noevir Co Ltd 皮膚外用剤
DE102006060439A1 (de) * 2006-12-19 2008-06-26 Henkel Kgaa Verbesserung der Hautverträglichkeit von hyperämisierenden Wirkstoffen
CA2740200C (en) * 2007-10-10 2015-01-13 Therametics, Llc Methods and compositions for treating dermatological diseases and conditions
JP2009149557A (ja) * 2007-12-20 2009-07-09 Shiseido Co Ltd 皮膚改善剤
DE102009055920A1 (de) * 2009-11-27 2011-06-01 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen enthaltend Kombinationen aus Zingeron und polyethoxylierten Verbindungen
DE102009055918A1 (de) * 2009-11-27 2011-06-01 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen enthaltend Kombinationen aus Zingeron und grenz- oder oberflächenaktiven Citronensäureestern
DE102009055917A1 (de) * 2009-11-27 2011-06-01 Beiersdorf Ag Verwendung von Zingeron gegen Altershaut
DE102009055919A1 (de) * 2009-11-27 2011-06-01 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen enthaltend Kombinationen aus Zingeron und grenz- oder oberflächenaktiven Polyglycerylverbindungen
FR2973229B1 (fr) * 2011-04-01 2013-03-29 Oreal Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 4-(3-ethoxy-4-hydroxyphenyl)alkylcetone ou 2-ethoxy 4-hydroxyalkyl phenol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747049A (en) * 1995-07-07 1998-05-05 Shiseido Company, Ltd. Cosmetic composition
JP2003206239A (ja) * 2001-12-28 2003-07-22 Lion Corp 温感組成物及び外用剤組成物
WO2011042358A1 (en) * 2009-10-08 2011-04-14 L'oreal Photoprotective composition based on a 2-alkoxy-4-alkyl ketone phenol compound; use of said compound for increasing the sun protection factor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chen, J.-C. et al., Journal of Agricultural and Food Chemistry Vol. 55 pages 8390-8397. Published 2007. *
Everyday Health: The Aging Effect of UV Rays (published online October 2009) *
Sandilands et al., (Journal of Cell Science Vol. 122 1285-1294. Published 2009). *

Also Published As

Publication number Publication date
BR112013025122A8 (pt) 2017-12-19
JP2014509631A (ja) 2014-04-21
EP3372220B1 (en) 2019-11-06
US11602496B2 (en) 2023-03-14
ES2767923T3 (es) 2020-06-19
US20180161257A1 (en) 2018-06-14
FR2973230B1 (fr) 2013-11-01
WO2012131072A1 (en) 2012-10-04
EP3372220A1 (en) 2018-09-12
EP2694025A1 (en) 2014-02-12
JP6282582B2 (ja) 2018-02-21
ES2673120T3 (es) 2018-06-19
BR112013025122A2 (pt) 2016-08-16
CN103957876A (zh) 2014-07-30
BR112013025122B1 (pt) 2018-05-29
FR2973230A1 (fr) 2012-10-05
EP2694025B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
US11602496B2 (en) Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing
US6753000B2 (en) Hydroxystilbene/ascorbic acid compositions for treating skin afflictions
US20080124312A1 (en) Polyamine Compositions
US8231916B2 (en) Use of a rice protein hydrolysate as pigmenting active principle
US20230381075A1 (en) Botanical and bacterial extracts displaying retinol-like activity
JP7071357B2 (ja) トリュフ抽出物およびネオヘスペリジンジヒドロカルコンを含む組成物
RU2501544C2 (ru) Композиция и способ лечения патологических состояний кожи
US6267971B1 (en) Use of cinnamic acid or of its derivatives in a cosmetic firming composition
JP2017110007A (ja) ピキア・アノマーラ及びチコリ根抽出物を含む局所用組成物
KR20150135433A (ko) 폴리고눔 비스토르타 추출물의 미용 또는 피부과 용도
CN110870880A (zh) 包含异常毕赤酵母和视黄醇的局部用组合物
US10328018B2 (en) Cosmetic use of the essential oil of Laserpitium siler L. against the signs of aging of the skin and as a skin antioxidant
US10071042B2 (en) External dermatological agent for anti-ageing
US10307353B2 (en) 1-phenylmono- or -polyhydroxypropane compounds, compositions and cosmetic uses thereof
KR20220016970A (ko) 로즈부시 추출물
NZ614250A (en) Composition comprising banyan tree, lotus, and clover serum fractions (hyperpigmentation)

Legal Events

Date Code Title Description
AS Assignment

Owner name: L'OREAL, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DALKO, MARIA;SAUSSAY, SOPHIE;SIGNING DATES FROM 20130919 TO 20130923;REEL/FRAME:031359/0661

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION